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Background: The heptitis B vaccine has been part of the South
African Expanded Programme on Immunization since April 1995
but its long-term impact remains unknown.
Methods & Materials: This study tested 1206 sera collected
frompatients aged1 to25years fromvarioushealth facilities across
the country for HBV serologicalmakers andHBVDNA. Based on the
year thevaccinewas introduced, sampleswere stratiﬁedbyage into
pre- and post-vaccine introduction populations, which were then
compared for evidence of immunity and chronic carriage using the
chi-square test.WhereHIV statuswas known, subset analyseswere
performed.
Results: Immunity to HBV infection increased from 13.0% in
the pre- to 57.0% in the post-vaccine introduction population
(p<0.001). This decreased with increasing age within the post-
vaccine introduction population (76.1% for 1-5 year olds, 50.0%
for 6-10 year olds and 46.3% for 11-16 year olds). In addition HBV
chronic carriage was signiﬁcantly (p=0.003) reduced in the post-
(1.4%) compared to the pre-vaccine introduction population (4.2%)
but increased with increasing age (0.5% in 1-5 year olds, 1.3% in
6-10 year olds and 2.2% in 11-16 year olds). The difference in
prevalence of activeHBV infection in the serologically exposed pre-
versus post-vaccine introduction populations was not statistically
signiﬁcant. Subset analyses showed that evidence of immunitywas
signiﬁcantly (p<0.001) higher in the HIV negative compared to the
HIV positive subset in both populations.
Conclusion: Universal hepatitis B vaccination has been a
remarkable success, with a signiﬁcant increase in immunity to HBV
infection. The observation that HBV chronic carriage increases as
immunitywanes over time calls into questionwhether the timehas
come to consider a pre-adolescence vaccine booster dose policy.
http://dx.doi.org/10.1016/j.ijid.2014.03.421
Type: Oral Presentation
Final Abstract Number: Pre.015
Session: Pre-Congress Symposium: Emerging African Investigators
Symposium
Date: Wednesday, April 2, 2014
Time: 13:00-17:00
Room: Room Roof Terrace
Virological proﬁles of hepatitis B virus
(HBV)-infected African patients treated with
tenofovir
H.F. Njai1,∗, A. Ceesay1, N. Bayzid1, G. Ndow1, M.
Lemoine1, Y. Shimakawa1, U. Dalessandro1, M.
Thursz2, M. Mendy3, I. Chemin4, R. Njie3
1 Medical Research Council (MRC), The Gambia Unit,
Fajara, Gambia
2 Imperial College, London, United Kingdom, London,
United Kingdom
3 International Agency for Research on Cancer
(IARC), Lyons, France
4 Centre de recherche en cancérologie –UMR
INSERM, Lyons, France
Background: There is an urgent need to screen, treat and clini-
callymanageHBV infection inAfrica, but standardized, reliable, low
cost viral load (VL) assaysarenot readily available.Herewedescribe
the implementation of an in-house VL assay in the current PRO-
LIFICA (Prevention of Liver Fibrosis and Cancer in Africa) project,
which aims at identifying and treating HBV-infected individuals to
reduce the incidence of liver cancer in West Africa.
Methods & Materials: A quantitative-Polymerase Chain Reac-
tion (PCR) assaywas developed in INSERM, Lyon, France. Following
training, technology was transferred to the Medical Research
Council Unit in The Gambia. Viral DNA extracted was quanti-
ﬁed using a quantitative real-time PCR assay with SYBR-Green
signal detection and speciﬁc primers that amplify a 98bp PCR
fragment.
Results: Seven hundred and seventy four (774) patients diag-
nosed with chronic HBV were tested for HBV VL, 65% (486/ 774)
showed detectable VL ranging from 5.0 x 101 – 2.0 x 1010 IU/ML.
Using the EASL (European Association for Study of the Liver)
guidelines, 30% (146/486) of patients had HBV VL>2,000IU/ML
and were eligible for treatment in conjunction with other clin-
ical criterion. To date, 68 patients are on Tenofovir treatment
of which 77% are male with a mean age of 38.0 +/- 12.6 years.
Data shows decline in HBV viral load by a mean of 1.5 log IU/Ml
(85% CI: 1.10-2.00) (P <0.001) over an average of 3.4 months
(+/- 3.0).
Conclusion: We have demonstrated the implementation of a
reliable low cost in-house q-PCR assay that can be used to monitor
the efﬁcacy of HBV therapy and useful in understanding the natural
history of HBV in an endemic area.
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